Actively Recruiting

Phase 1
Age: 50Years - 80Years
All Genders
NCT07064005

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Led by Pravat Mandal · Updated on 2026-05-04

12

Participants Needed

1

Research Sites

87 weeks

Total Duration

On this page

Sponsors

P

Pravat Mandal

Lead Sponsor

W

Waste Connections Inc

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

CONDITIONS

Official Title

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Who Can Participate

Age: 50Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed Parkinson's Disease diagnosis.
  • Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
  • Age 50 to 80 years.
  • Ability to read and write in English.
Not Eligible

You will not qualify if you...

  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
  • Subjects with claustrophobia.
  • Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
  • Subjects with a history of cancer.
  • Subjects with active psychosis or delirium.
  • Subjects with chronic kidney (creatinine > 1.5mg/dL) or liver disease (AST 21 1.5 ULN; ALT 21 1.5 ULN) within 30 days prior to enrolment.
  • Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl).
  • Subjects with previous traumatic head injury.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

Loading map...

Research Team

P

Pravat K MANDAL, PHD

CONTACT

N

Nazia Pillar, M.S

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here